Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory neurotransmitter ␥-aminobutyric acid. It is an ␣ 2 -␦ (␣ 2 -␦) ligand that has analgesic, anticonvulsant, anxiolytic, and sleep-modulating activities. Pregabalin binds potently to the ␣ 2 -␦ subunit of calcium channels, resulting in a reduction in the release of several neurotransmitters, including glutamate, noradrenaline, serotonin, dopamine, and substance P. In this review, I will discuss the pharmacology of pregabalin and available efficacy studies in pain management. This review will focus on the advances in pregabalin pharmacology since my previous review in 2005.
Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory neurotransmitter ␥-aminobutyric acid. It is an ␣ 2 -␦ (␣ 2 -␦) ligand that has analgesic, anticonvulsant, anxiolytic, and sleep-modulating activities. Pregabalin binds potently to the ␣ 2 -␦ subunit of calcium channels, resulting in a reduction in the release of several neurotransmitters, including glutamate, noradrenaline, serotonin, dopamine, and substance P. In this review, I will discuss the pharmacology of pregabalin and available efficacy studies in pain management. This review will focus on the advances in pregabalin pharmacology since my previous review in 2005. Thi s review will focus on the advances in pregabalin pharmacology and the latest studies since my previous review in 2005 (1) . Anticonvulsant medications are established treatments for neuropathic pain (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Pregabalin (S-[ϩ]-3-isobutylgaba) was designed as a lipophilic GABA (␥-aminobutyric acid) analog substituted at the 3Ј-position to facilitate diffusion across the blood-brain barrier (12) (13) (14) . Pregabalin, like gabapentin, was shown to be effective in several models of neuropathic pain (15) (16) (17) , incisional injury (18) , inflammatory injury (13, 19) , and formalin-induced injury (13) . It is also effective in the treatment of anxiety, and is also a sleep-modulating drug (18 -32) . Pregabalin increases the duration of nonrapid eye movement and also decreases rapid eye movement sleep in rats (20) . In addition, pregabalin has been shown to increase slow-wave sleep in healthy volunteers. Slowwave sleep has been correlated with the restorative aspects of sleep (33) . Pregabalin treatment has been shown to significantly increase the time spent in stages III-IV sleep while decreasing nighttime awakenings (34) .
The European Commission, granted Pfizer approval for pregabalin (Lyrica™, Pfizer, New York, NY) in July 2004 in all European Union member states for the treatment of peripheral neuropathic pain and as an adjunctive therapy for partial seizures in patients with epilepsy. The approval was based on results from 10 trials studying more than 9000 patients. In December 2004, the Food and Drug Administration approved pregabalin, for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN), under the trade name Lyrica. In June 2005, pregabalin was approved as an adjunctive treatment of partial onset epilepsy in adults. More recently, in March 2006, the European Commission approved pregabalin for the treatment of generalized anxiety disorder. The Drug Enforcement Administration has placed pregabalin into Schedule V of the Controlled Substances Act (35) , based on results of a small study of 15 recreational "nondependent" drug users, reports of euphoria in controlled clinical trials, and adverse events that were observed when pregabalin was abruptly discontinued.
MECHANISM OF ACTION
The precise mode of action of pregabalin has not been fully elucidated, but it does interact with the same binding site, and has a similar pharmacologic profile, as gabapentin (1-[aminomethyl] cyclohexane acetic acid) (36 -39) . Its main site of action appears to be on the ␣ 2 -␦ subunit of presynaptic, voltagedependent calcium channels (Fig. 1 ) that are widely distributed throughout the peripheral and central nervous system (40 -47) . Binding affinity for the ␣ 2 -␦ subunit, and potency, is six times more than that of gabapentin (48) . Up-regulation of the ␣ 2 -␦ subunit may play an important role in hypersensitization processes (49) . Pregabalin appears to produce an inhibitory modulation of neuronal excitability (50) , particularly in areas of the central nervous system dense in synaptic connections such as the neocortex, amygdala, and hippocampus (51, 52) . Ectopic activity is reduced while normal nerve function is unchanged (53) . As with gabapentin, pregabalin is inactive at GABA A and GABA B receptors, is not converted metabolically into GABA or a GABA antagonist, and it does not alter GABA uptake or degradation (54 -56).
Voltage-dependent calcium channels have been divided into six classes, based on their voltage dependence, kinetics, and sensitivity to a range of drugs (57, 58) . The molecular structure of these functionally identified P-, Q-, N-, L-, R-, and T-type calcium channels has now been determined (59) . N-type calcium channels are thought to have a role in pain sensitization processes (60, 61) . Calcium channels are made up of five subunits. Pregabalin binds potently to the ␣ 2 -␦ subunit and modulates calcium influx at nerve terminals, and, thereby, reduces the release of several neurotransmitters, including glutamate, noradrenaline, serotonin, dopamine, and substance P (62) (63) (64) (65) (66) (67) (68) . Dihydopyridines, such as verapamil, are selective for L-type calcium channels (69) . In contrast to these medications, pregabalin has no effect on arterial blood pressure or cardiac function.
Studies have been conducted using the R217A mutant mouse that has a single amino acid substitution of arginine to alanine at position 217 in the ␣ 2 -␦ subunit, which is presumed to alter its conformation. In these mutant mice, pregabalin binding at the ␣ 2 -␦ subunit is reduced as is its analgesic action, supporting the hypothesis that the analgesic actions of pregabalin are mediated through its binding to the ␣ 2 -␦ subunit of voltage-gated calcium channels (70) . The mutant mice had otherwise typical responses to analgesic drugs, such as amitriptyline and morphine, and normal pain thresholds.
DOSAGE AND ADMINISTRATION
For painful DPN, the maximum recommended dose of pregabalin is 100 mg thrice a day (300 mg/day). Dosing should begin at 50 mg thrice a day (150 mg/day) and may be increased to 300 mg/day within 1 wk based on efficacy and tolerability. Because pregabalin is eliminated primarily by renal excretion, the dose should be adjusted for patients with reduced renal function. Although pregabalin was also studied at 600 mg/day, which was less well tolerated, there is no evidence that this dose confers additional significant benefit. In view of the dose-dependent adverse effects, treatment of DPN patients with doses larger than 300 mg/day is not recommended.
For PHN, dosing should begin at 75 mg twice a day, or 50 mg thrice times a day (150 mg/day) and may be increased to 300 mg/day within 1 wk based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2-4 wk of treatment with 300 mg/day, and who are able to tolerate pregabalin, may be treated with up to 300 mg twice a day, or 200 mg thrice a day (600 mg/day).
Converting patients from gabapentin to pregabalin has not been studied. Gabapentin should be discontinued over a minimum of 1 wk before starting pregabalin at a dose of 150 mg/day. There is no contraindication to adding pregabalin to gabapentin, but side effects may be additive.
PHARMACOKINETICS
Absorption of gabapentin is limited by saturable, active, dose-dependent transport in the gastrointestinal tract (71) . Therefore, smaller doses, given more frequently, may be required to optimize absorption. Absorption of pregabalin is not saturable, resulting in a linear pharmacokinetic profile (72, 73) . In healthy volunteers, pregabalin is rapidly absorbed with peak blood concentrations within 1 h (74 -76). Average bioavailability exceeds 90% and is independent of dose, which may produce a more predictable patient response. The elimination half-life of pregabalin ranges from 5.5 to 6.7 h, and is independent of dose and repeated dose administration. In contrast to pregabalin, the rate of gabapentin absorption is relatively slow, with peak plasma concentrations occurring around 3 h postdose.
Pregabalin does not undergo hepatic metabolism and is not bound to plasma proteins. It is renally excreted, and 98% of the absorbed dose is excreted unchanged in the urine. Pregabalin elimination is nearly proportional to creatinine clearance. Pregabalin clearance is reduced in subjects with impaired renal function. A 50% reduction in pregabalin daily dose is recommended for patients with creatinine clearance (CLcr) between 30 and 60 mL/min compared with those with CLcr Ͼ60 mL/min (77) . After a 4-h hemodialysis treatment, plasma pregabalin concentrations are reduced by approximately 50%.
No pharmacokinetic drug-drug interactions have been identified in formal interaction studies and, based on the pharmacokinetic profile, none is expected (78, 79) .
SIDE EFFECTS AND PRECAUTIONS
Pregabalin is well tolerated (80) and associated with dose-dependent adverse effects that are mild-tomoderate and are usually transient (Table 1 ). In clinical trials, dizziness and somnolence are the most frequently reported adverse events, with dizziness experienced by 29% of pregabalin-treated patients compared with 9% with placebo and somnolence, experienced by 22% of pregabalin-treated patients compared with 8% with placebo (81). Dose-dependent weight gain has been reported (82) . There have been case reports of myoclonus (83) aterixis (84), gynecomastia (85) , and a single case report has described encephalopathy and edema of the corpus callosum after abrupt discontinuation of pregabalin (86) .
As with all antiepileptic drugs, pregabalin should be withdrawn gradually to minimize the potential of increased seizure frequency in patients with seizure disorders. If pregabalin is discontinued, the dose should be gradually tapered over a minimum of 1 wk. There are no head-to-head studies comparing the side effects of pregabalin versus gabapentin. The trials involving gabapentin have usually used variable doses (87, 88) , whereas the trials with pregabalin used fixed dosing without titration. Differences in study design may influence the reported incidence of side effects. Nonetheless, comparing available studies, side effect profiles appear similar, with the exception perhaps of a more frequent incidence of nausea and diarrhea with gabapentin (89) . Pregabalin is contraindicated in patients with a known hypersensitivity to pregabalin or any of its components.
STUDIES

Volunteer Studies
Thirty-two healthy volunteers received either oral pregabalin (titrated to 300 mg) or aprepitant, an NK 1 antagonist (titrated to 320 mg), or matching placebo over 6 days (50). Aprepitant was used as an example of a drug class active in animal models, but not in neuropathic pain patients. Central sensitization was then invoked by repetitive stimulation of the skin. Sensitization was assessed over 3 h. At 2 h, subjects received either parecoxib (40 mg) or IV saline. Pregabalin significantly reduced the areas of punctate mechanical hyperalgesia and dynamic touch allodynia versus placebo. No significant reduction in the area of hyperalgesia or allodynia versus placebo was observed with aprepitant. In the pregabalin and parecoxib-treated group, the area of allodynia was significantly reduced and the area of hyperalgesia insignificantly attenuated versus placebo and parecoxib. No efficacy improvement was observed with aprepitant and parecoxib.
Painful DPN Rosenstock et al. (90) evaluated the effectiveness of pregabalin in alleviating pain associated with DPN. Patients were randomized to receive placebo or pregabalin 100 mg TID, without an initial titration phase. The primary efficacy measure was end-point mean pain score from daily patient diaries (11- In a study by Lesser et al. (91) , patients were randomized to receive pregabalin 300 or 600 mg/day or placebo. Pregabalin 600 mg/day was titrated over 6 days; smaller doses were initiated on day 1. Patients in the pregabalin 300 and 600 mg/day pregabalin groups showed improvements in end-point mean pain score compared with those in the placebo. Improvements were also seen in weekly pain score, sleep interference score, PGIC, CGIC, SF-MPQ, and multiple domains of the SF-36 Health Survey. Improvements in pain and sleep were seen as early as week 1 and were sustained throughout the 5-wk study period. Responders (50% reduction in pain compared with baseline) were 46% (300 mg/day), 48% (600 mg/day), and 18% (placebo). For this responder rate analysis, patients who did not complete the study were assigned a 0% improvement, known as baseline observation carried forward analysis. There was no evidence of a greater effect on pain scores of the 200 mg TID dosing compared with 100 mg TID, but there was evidence of dose-dependent adverse events. Pregabalin was well tolerated with a low discontinuation rate. The most common adverse events were dizziness and somnolence.
A 6-wk, randomized, double-blind, multicenter study evaluated the efficacy of pregabalin in the treatment of painful DPN (92) . Patients with DPN received pregabalin (50 mg or 200 mg TID) or placebo. The primary efficacy variable was mean pain score at the end of treatment. Pregabalin 600 mg/day significantly decreased mean pain score to 4.3 (versus 5.6 for placebo) and increased the proportion of patients who had a Ն50% decrease from baseline pain (39% vs 15% for placebo). Pregabalin also significantly reduced sleep 
pain as gnawing, sickening, fearful, and punishingcruel. More patients receiving pregabalin 600 mg/day than placebo showed improvement, as rated on the PGIC/CGIC scales, 73% vs 45% and 85% vs 47%, respectively. Pregabalin 150 mg/day was essentially no different from placebo. Dizziness was the most common side effect.
PHN
Sabatowski et al. (82) assessed the efficacy and safety of pregabalin for treating neuropathic pain in patients with PHN. Patients were randomized to receive pregabalin 150 mg/day, pregabalin 300 mg/day, or placebo for 8 wk. Those who had failed to respond to previous treatment with gabapentin at doses of 1200 mg/day or more were excluded. Patients were allowed to continue a stable treatment regime of acetaminophen (up to 3 g/day), nonsteroidal antiinflammatory drugs, opioid or non-opioid analgesics, or antidepressants. End-point mean pain scores were significantly reduced in patients receiving pregabalin 150 mg/day or 300 mg/day compared with placebo. Efficacy was observed as early as week 1, and was maintained throughout the study. Significantly, more patients in both pregabalin groups (150 mg, 26%; 300 mg, 28%) were responders (50% or more decrease in mean pain score from baseline to end point) than in the placebo group (10%). Additionally, by week 1 and for the study's duration, pregabalin 150 and 300 mg/day significantly reduced weekly mean sleep interference scores. More patients in the pregabalin group reported that they were "much improved" or "very much improved" compared with patients in the placebo group. Health-related qualityof-life measurements using the SF-36 Health Survey demonstrated improvement in the mental health domain for both pregabalin dosages, and bodily pain and vitality domains were improved in the 300 mg/day group. The most frequent adverse events were dizziness, somnolence, peripheral edema, headache, and dry mouth.
Dworkin et al. (93) conducted a multicenter, parallelgroup, double-blind, placebo-controlled, 8-wk, randomized clinical trial in PHN, defined as pain for three or more months after herpes zoster rash healing. Patients were randomized to receive pregabalin either 600 mg/day (CLcr Ͼ60 mL/min) or 300 mg/day (CLcr 30 -60 mL/min). The primary efficacy measure was the mean of the last seven daily pain ratings. Secondary end points included additional pain ratings, sleep interference, quality-of-life, mood, and patient and clinician ratings of global improvement. Pregabalintreated patients had greater decreases in pain than patients treated with placebo (end-point mean scores 3.60 vs 5.29). Pain was significantly reduced in the pregabalin-treated patients after the first full day of treatment and throughout the study, and significant improvement on the SF-MPQ total, sensory, and affective pain scores was also found. The proportions of patients with 30% or more and 50% or more decreases in mean pain scores were larger in the pregabalin than in the placebo group (63% vs 25% and 50% vs 20%). Sleep also improved in patients treated with pregabalin compared with placebo. Both patients and clinicians were more likely to report global improvement with pregabalin than with placebo. The number needed to treat (NNT) is the number of patients needed to be treated by an intervention to obtain a defined outcome (94) . In this study, the NNT for pregabalin-associated decreases in end-point mean pain scores Ն30% was 2.7 and for decreases in end-point mean pain scores Ն50% was 3.4. These NNT are comparable to previous studies of gabapentin, tricyclic antidepressants, and opioid analgesics (95) (96) (97) (98) (99) . Also, although few systematic comparisons of differences in side effects among the medications used in the treatment of PHN have been conducted (97) , the number needed to harm for pregabalin based on all side effects was 4.3, which is also comparable to previous studies of gabapentin, tricyclic antidepressants, and opioid analgesics (97, 99, 100) . Thirty-two percent of subjects discontinued pregabalin because of dizziness, somnolence, or other side effects, compared with 5% receiving placebo.
van Seventer et al. (31) evaluated the efficacy and safety of pregabalin 75, 150, or 300 mg given BID compared with placebo in patients with PHN. Patients with pain for Ն3 mo after skin rash healing were randomized in a multicenter, 13-wk, double-blind, placebo-controlled study. Compared with placebo, all dosages of pregabalin were significantly more effective at relieving pain. Weekly mean pain scores in each pregabalin group were also significantly improved, compared with placebo, by week 1, and improvement was maintained through week 13. Most adverse events were mild or moderate, and only 13% of patients treated with pregabalin and 4% of patients in the placebo group withdrew because of treatmentrelated adverse events. Among pregabalin-treated patients, the adverse events that most often led to discontinuation were dizziness, somnolence, and ataxia.
Other Neuropathic Pain Studies A12-wk randomized, double-blind, multicenter, placebo-controlled, parallel-group study evaluated the efficacy and safety of pregabalin in patients with PHN or painful DPN (101) . Patients were randomized to receive placebo or 1 of 2 pregabalin regimens: a flexible schedule of 150, 300, 450, and 600 mg/day with weekly dose escalation based on patients' individual responses and tolerability or a fixed schedule of 300 mg/day for 1 wk, followed by 600 mg/day for 11 wk. Both flexible-and fixed-dose pregabalin significantly reduced end-point mean pain score versus placebo. The NNT for at least a 50% reduction in pain was calculated to be 3.6 for patients in the fixed-dose arm, 4.2 for patients in the flexible-dose arm, and 3.8 for all pregabalin-treated patients. The most common adverse events for pregabalin-treated patients were dizziness, peripheral edema, weight gain, and somnolence.
D'Urso De Cruz et al. (102) evaluated the long-term efficacy and safety of pregabalin for the treatment of neuropathic pain associated with DPN or PHN in treatment-refractory patients. All patients had previously participated in double-blind or open-label trials. Patients had documented inadequate pain relief or intolerable adverse events to a tricyclic antidepressant (Ն75 mg/d, Ն2 wk); gabapentin (Ն1800 mg/d, Ն2 wk); and a third-line pain treatment (Ն2 wk). Patients received pregabalin 150 -600 mg/day titrated to effectiveness and tolerability. Concomitant analgesics, including gabapentin, were allowed as needed. Pregabalin was discontinued during a drug holiday at 3-mo intervals to evaluate the continuing presence of neuropathic pain and the continuing need for treatment. Only patients whose pain relapsed during a drug holiday (i.e., pain became moderately, much, or very much worse) resumed trial participation. Baseline visual analog scale scores for DPN and PHN patients were 73 and 75 mm. At the end of the first 15 study months, mean visual analog scale scores for DPN and PHN patients were 47 and 48 mm. At 3 mo, 45% and 36% of DPN and PHN patients reported pain reductions Ն50%, and at 15 mo, 36% and 38% of patients reported similar reductions. The median duration of drug holidays was 3 days. All but four patients experienced pain exacerbation during drug holidays. Most common adverse events were dizziness, somnolence, and peripheral edema. Ten patients withdrew because of adverse events. It is noteworthy that two studies did not exclude gabapentin nonresponders (31, 101) .
A 12-wk, multicenter study randomized patients to receive flexible-dose pregabalin 150 -600 mg/day or placebo administered BID (103) . Patients were allowed to continue on existing, stable pain therapy. The primary efficacy variable was the end-point mean pain score, derived from patients' last 7 days daily pain diary entries. Key secondary end points included pain responder rates, the SF-MPQ, sleep interference, mood, and the PGIC. The mean end-point pain score was lower in the pregabalin group (4.62) than in the placebo group (6.27; P Ͻ 0.001), with efficacy observed as early as week 1 and maintained for the duration of the study. The average pregabalin dose after the 3-wk stabilization phase was 460 mg/day. Pregabalin was significantly superior to placebo in end-point assessments on the SF-MPQ. The 30% and 50% pain responder rates were higher with pregabalin than with placebo (42% and 22%, respectively). Pregabalin was associated with improvements in disturbed sleep and anxiety, and more patients reported global improvement at end-point assessments in the pregabalin group. Somnolence and dizziness were the most common adverse events and were mild or moderate, and typically transient.
Fibromyalgia
The efficacy and safety of pregabalin up to 450 mg/day (150 mg thrice daily) were evaluated for reducing pain and associated symptoms in patients with fibromyalgia (104) . Patients were randomized to receive 150, 300, or 450 mg/day of pregabalin or placebo. Compared with those receiving placebo, patients treated with pregabalin 450 mg/day showed significant improvement in pain scores at week 1, and this was maintained throughout week 7. However, there was no statistically significant improvement from placebo at week 8. Reasons for the loss of a statistically significant difference at week 8 may include reduced statistical power at later time points or lack of durability of analgesic effect. Patients receiving 300 and 450 mg/day pregabalin also experienced reduced fatigue and improved sleep quality compared with those receiving pregabalin 150 mg/day or placebo. Forty-eight patients (9%) withdrew because of adverse events, and 44 patients (8%) withdrew because of lack of efficacy. The most common adverse events were dizziness and somnolence.
Acute Pain
Sensitization of dorsal horn neurons has been demonstrated in acute pain models (105, 106) and may also play a role in the development of chronic pain after surgery (107, 108) . By reducing the hyperexcitability of dorsal horn neurons induced by tissue damage, gabapentin and pregabalin may have roles in the treatment of postoperative pain (109 -111) . However, the optimal doses of these medications still require further study (112) . Since patients may be anxious in the perioperative period, the anxiolytic effects of gabapentin and pregabalin may be beneficial. In addition, gabapentin, and perhaps pregabalin, may prevent opioid tolerance (113, 114) . Interestingly, gabapentin and pregabalin may have some therapeutic use in the treatment of opioid dependence (115). A randomized, double-blind, placebo-controlled, parallel-group trial was performed to compare pregabalin 50 and 300 mg with placebo and ibuprofen 400 mg using a dental pain model (116) . Study medication was administered postoperatively to patients who had undergone elective surgery to remove one-or twothird molars, at least one of which was mandibular and fully or partially impacted in bone. Primary efficacy variables included pain relief, pain intensity difference, pain relief intensity difference, time to onset of analgesia, and duration of analgesia. The patient's global impression of the study medication was used as a secondary efficacy variable. There were statistically significant differences in pain relief, pain intensity difference, and pain relief intensity difference between the 300 mg pregabalin group and placebo. In addition, the 300 mg pregabalin group had a significantly longer duration of analgesia than the ibuprofen group and had the highest score on the patient global impression of study medication. The median time to onset of analgesia was shorter for patients treated with ibuprofen (16 min) than for those receiving pregabalin 300 mg (23.5 min), although this difference was not statistically significant. Adverse events were reported more often in the pregabalin 300 mg group. Of the 50 patients receiving pregabalin 300 mg, 24 (48%) experienced side effects, most commonly dizziness, somnolence, and vomiting. Interestingly, another study in a rat model suggested that the use of gabapentin or pregabalin in small-dose combinations with naproxen may afford therapeutic advantages for clinical treatment of persistent inflammatory pain (117) .
In a recent study, 80 patients undergoing elective spinal fusion surgery were randomized to receive placebo, celecoxib 400 mg, pregabalin 150 mg, or a combination of celecoxib 400 mg and pregabalin 150 mg orally 1 h before induction of anesthesia (118) . Patients underwent general anesthesia. Postoperatively, patients received patient-controlled analgesia using morphine. Twelve hours after initial study drug administration, patients were given placebo, celecoxib 200 mg, pregabalin 150 mg, or a combination of celecoxib 200 mg and pregabalin 150 mg orally. The combination of pregabalin and celecoxib significantly reduced pain and opioid use compared with the use of either analgesic alone.
SUMMARY AND FUTURE DIRECTIONS
Pregabalin is a new synthetic molecule with a favorable pharmacokinetic profile compared with gabapentin (Table 2) . Analgesic efficacy for neuropathic pain has been well studied and significant decreases in pain scores are typically seen by day 2 (119) ( Table 3) . Pregabalin is a valuable addition to the still-limited options for the treatment of neuropathic pain (120 -129) and may be more cost-effective than high doses of gabapentin (130, 131) . It can be effective in patients who have previously failed to respond to gabapentin (102) . Studies are required to define outcomes, benefits, and side effects compared with gabapentin as well as other therapies for neuropathic pain (132, 133) . The mechanism of action of pregabalin also requires further study. Pregabalin will likely be studied as part of a multimodal approach to pain management and, like gabapentin, is likely to prove useful for the treatment of a wide variety of chronic pain (134 -154) syndromes as well as for acute postoperative pain (155) and inflammatory pain. Other uses of pregabalin also need to be more clearly defined (156, 157) .
